Lilleta IUD abortifacient contraception levonorgestrel Medicines360 FDA
Liletta (levonorgestrel) Intrauterine Device – formerly Levosert
Company: Medicines360 and Actavis plc
Date of Approval: February 27, 2015
Treatment for: Contraception [abortifacient mechanism of action, chemically and mechanically]
Liletta (levonorgestrel) is a hormonal intrauterine device (IUD) for use by women to prevent pregnancy for up to three years. The basic mechanism of action is abortifacient by action of the progestin levonorgestrel–which is poor at supressing ovulation–and the mechanical irritation of the endometrium after junior has been conceived and implanted in the womb.
- FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Three Years– February 27, 2015
- Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert IUD– July 21, 2014